COX-2

Approved by the FDA in 2001, Bextra is a part of a new class of NSAIDs, the COX 2 selective drugs.

Selective COX 2 drugs, also including Vioxx and Celebrex were created to decrease stomach, kidney and gastrointestinal problems and are believed to work by inhibiting the cyclooxygenase enzyme that is specifically responsible for inflammation and pain.

Pfizer marketed Bextra under the context that it is unlike traditional NSAIDs that target all cyclooxygenase enzymes which includes COX 1.

However, inhibiting strictly COX 2 enzymes creates an imbalance that leads to pro-thrombotic events. 

COX 2 enzymes are mostly known for spurring inflammation and pain, but this enzyme also aids in the maintenance of healthy platelet activity (important for minimizing adverse cardiovascular events such as heart attacks and strokes).

Patients may be trading gastrointestinal complications for cardiovascular risks when switching from non-selective NSAIDs to COX 2 selective drugs.

Inhibiting strictly COX 2 enzymes create a higher level of COX 1 enzymes that are known for promoting vasoconstriction and platelet aggregation.

Each COX-2 selective drug are varied structurally, but they virtually have the same risk profile; that which includes increased cardiovascular risk, gastrointestinal events, and with the drug Bextra and Celebrex (in some patients) severe skin disorders.

If you or a loved one has suffered due to a side effect of Bextra, you can fill out this simple form for a free case review within 24 hours.

Weitz & Luxenberg is no longer accepting Bextra cases.

see also:

NSAID Bextra Attorney - Basic Information on Bextra, from Bextra Attorneys
Bextra Vioxx Celebrex and other NSAIDs are dangerous - Bextra Attorney

History Bextra Lawsuit - The History of Bextra
History of Bextra

Basic Information Bextra Attorney - Basic Information on Bextra, from Bextra Attorneys
Bextra Vioxx Celebrex and other NSAIDs are dangerous - Bextra Attorney